MedTrace Logo

Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer

NCT04869371 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2022-12-29

No results posted yet for this study

Summary

This randomized, controlled, single center clinical trial aims to evaluate the efficacy and safety of Androgen Deprivation Therapy Combined with Docetaxel for High Risk Prostate Cancer with a six-month treatment cycle.

Conditions

  • Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel

Interventions

DRUG

Docetaxel injection

75 mg/m2 body surface area every 3 weeks for 6 cycles before robot assisted radical prostatectomy

DRUG

Triptorelin Pamoate for Injectable Suspension

15mg every 12 weeks

DRUG

Prednisone Acetate Tablets

5 mg oral low dose prednisone, once daily

Sponsors & Collaborators

  • Hongqian Guo

    lead OTHER

Principal Investigators

  • Hongqian Guo, MD · Nanjing Drum Tower Hospital, affiliated to medical school of Nanjing University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-12
Primary Completion
2020-12-01
Completion
2023-01-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04869371 on ClinicalTrials.gov